SG Americas Securities LLC Acquires New Shares in BeOne Medicines Ltd. – Sponsored ADR $ONC

SG Americas Securities LLC bought a new position in BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 2,787 shares of the company’s stock, valued at approximately $950,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Parallel Advisors LLC bought a new stake in shares of BeOne Medicines in the 2nd quarter valued at approximately $59,000. Farther Finance Advisors LLC acquired a new stake in BeOne Medicines in the second quarter valued at approximately $39,000. Avanza Fonder AB acquired a new stake in BeOne Medicines in the second quarter valued at approximately $199,000. Public Employees Retirement System of Ohio bought a new stake in BeOne Medicines in the second quarter worth approximately $3,491,000. Finally, Perigon Wealth Management LLC acquired a new position in shares of BeOne Medicines during the 2nd quarter worth $581,000. 48.55% of the stock is owned by hedge funds and other institutional investors.

BeOne Medicines Trading Down 0.0%

BeOne Medicines stock opened at $338.19 on Tuesday. BeOne Medicines Ltd. – Sponsored ADR has a 52 week low of $196.45 and a 52 week high of $385.22. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.17 and a current ratio of 2.39. The firm has a market capitalization of $37.09 billion, a PE ratio of 663.12 and a beta of 0.47. The business’s 50-day simple moving average is $330.41 and its 200-day simple moving average is $317.93.

Insiders Place Their Bets

In related news, Director Corazon (Corsee) D. Sanders sold 2,627 shares of the company’s stock in a transaction on Wednesday, November 26th. The shares were sold at an average price of $340.90, for a total transaction of $895,544.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Xiaobin Wu sold 10,000 shares of the firm’s stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $356.02, for a total transaction of $3,560,200.00. Following the completion of the sale, the chief operating officer owned 6,009 shares in the company, valued at $2,139,324.18. This represents a 62.46% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 128,610 shares of company stock valued at $41,114,068. Corporate insiders own 6.62% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. Morgan Stanley reaffirmed an “overweight” rating and issued a $405.00 price objective on shares of BeOne Medicines in a research note on Thursday, January 8th. Wall Street Zen raised BeOne Medicines from a “buy” rating to a “strong-buy” rating in a research report on Friday, October 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of BeOne Medicines in a report on Wednesday, October 8th. Citizens Jmp boosted their target price on BeOne Medicines from $348.00 to $396.00 and gave the stock a “market outperform” rating in a report on Friday, November 7th. Finally, Sanford C. Bernstein raised BeOne Medicines from a “hold” rating to an “outperform” rating and set a $414.00 target price for the company in a research report on Monday, January 12th. Thirteen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $378.43.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.